Key result
Recombinant apo(a) reduces endogenous thrombolysis by ~5 percentage points in venous thrombosis.
Answers are grounded in this paper and cite their sources.
Demonstrates the impact of apolipoprotein(a) on thrombolysis in rabbits, suggesting relevance in cardiovascular disease.
BACKGROUND: In many case-control as well as epidemiological studies, increased lipoprotein(a) [Lp(a)] levels are considered to constitute an independent risk factor for premature coronary artery and cerebrovascular disease. Lp(a) resembles an LDL particle with an additional linked protein [apolipoprotein(a), apo(a)], whose molecular structure has been demonstrated to be homologous to the fibrinolytic proenzyme plasminogen. Because of the high similarity between plasminogen and apo(a), apo(a) may potentially interfere in the fibrinolytic system by competing with plasminogen for fibrin binding sites. In vitro studies have demonstrated that Lp(a) indeed competes with plasminogen binding to fibrin and inhibits tissue plasminogen activator (TPA)-mediated activation of plasminogen. No direct in vivo studies to test this hypothesis have been performed. METHODS AND RESULTS: To test this hypothesis, we studied the effect of a recombinant form of apo(a) on endogenous and TPA-mediated thrombolysis in an in vivo model of experimental venous thrombosis. Thrombi containing either 16 microg r-apo(a), 8 microg r-apo(a), or vehicle (HEPES-buffered saline, control) were formed in the jugular veins of a rabbit and showed significantly reduced endogenous thrombolysis after 60 minutes in a dose-dependent fashion, ID 2.7+/-0.9% and 4.6+/-1.8%, respectively, versus 7.4+/-1.6% of that of the control. High concentrations of incorporated apo(a) significantly reduced TPA-induced thrombolysis (12.2+/-2.5% versus 22.2+/-2.6% in the control thrombi), but no effect of lower concentrations of incorporated r-apo(a) was demonstrated on the exogenous TPA-induced thrombolysis. CONCLUSIONS: The present study demonstrates the attenuation of endogenous fibrinolysis by apo(a) in an in vivo model of experimental venous thrombosis, lending support to the proposed mechanism of impaired fibrinolysis by which Lp(a) may contribute to atherothrombotic disorders.
No takes yet. Share an insight, caveat, or question.
Biemond et al. (1997) studied Experimental venous thrombosis. Recombinant apolipoprotein(a) vs. Vehicle (HEPES-buffered saline) was evaluated on Endogenous thrombolysis at 60 minutes. Recombinant apolipoprotein(a) dose-dependently reduced endogenous thrombolysis and TPA-induced thrombolysis in a rabbit model of venous thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: